MET and RANBP9

Number of citations of the paper that reports this interaction (PubMedID 12147692)
46

Data Source:
HPRD (two hybrid, in vivo, in vitro)

		MET	RANBP9
Description		MET proto-oncogene, receptor tyrosine kinase	RAN binding protein 9
Image
GO Annotations	Cellular Component	Extracellular Region Plasma Membrane Integral Component Of Plasma Membrane Basal Plasma Membrane Cell Surface Integral Component Of Membrane Receptor Complex	Ubiquitin Ligase Complex Nucleus Cytoplasm Cytosol Microtubule Associated Complex Plasma Membrane
	Molecular Function	Protein Tyrosine Kinase Activity Transmembrane Receptor Protein Tyrosine Kinase Activity Hepatocyte Growth Factor-activated Receptor Activity Protein Binding ATP Binding Semaphorin Receptor Activity Protein Phosphatase Binding Identical Protein Binding	Protein Binding Ran GTPase Binding Enzyme Binding
	Biological Process	MAPK Cascade Endothelial Cell Morphogenesis Liver Development Signal Transduction Cell Surface Receptor Signaling Pathway Transmembrane Receptor Protein Tyrosine Kinase Signaling Pathway Multicellular Organism Development Negative Regulation Of Autophagy Peptidyl-tyrosine Phosphorylation Neuron Differentiation Pancreas Development Positive Regulation Of Microtubule Polymerization Positive Regulation Of Kinase Activity Negative Regulation Of Rho Protein Signal Transduction Entry Of Bacterium Into Host Cell Positive Regulation Of Transcription By RNA Polymerase II Hepatocyte Growth Factor Receptor Signaling Pathway Branching Morphogenesis Of An Epithelial Tube Positive Chemotaxis Negative Regulation Of Stress Fiber Assembly Positive Regulation Of Protein Kinase B Signaling Establishment Of Skin Barrier Negative Regulation Of Thrombin-activated Receptor Signaling Pathway Semaphorin-plexin Signaling Pathway Negative Regulation Of Hydrogen Peroxide-mediated Programmed Cell Death Negative Regulation Of Guanyl-nucleotide Exchange Factor Activity Positive Regulation Of Endothelial Cell Chemotaxis	MAPK Cascade Microtubule Nucleation Axon Guidance Protein-containing Complex Assembly Negative Regulation Of ERK1 And ERK2 Cascade
Pathways		PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels	L1CAM interactions RAF/MAP kinase cascade MET activates RAS signaling
Drugs		K-252a 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol 6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Tivantinib Brigatinib Amuvatinib
Diseases		Renal cell carcinoma Cholangiocarcinoma Gastric cancer
GWAS		Blood protein levels ( 30072576) Gamma glutamyl transferase levels ( 29403010) HDL cholesterol levels ( 28334899) Hematocrit ( 28017375) Lung function (FEV1/FVC) ( 30804560) Medication use (beta blocking agents) ( 31015401) Multiple sclerosis (severity) ( 19010793) PR segment ( 24850809) Pulse pressure ( 30578418) Resting heart rate ( 29769521 27798624) Triglyceride levels ( 28334899) Triglycerides ( 24097068) Waist-to-hip ratio adjusted for BMI ( 26426971) Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) ( 26426971)	Breast cancer ( 29059683 23535729)
Interacting Genes		61 interacting genes: BAG1 CASP3 CBL CCND2 CD44 CDK4 CDK6 CDKN2B CNR1 CTNNB1 CTTN DAPK3 DCN DNAJA3 EGFR EPHA2 ERBB2 FAS FGFR4 FZR1 GAB1 GLIS2 GLMN GRB2 HGF HGS INPP5D INPPL1 ITGB1 ITGB4 KDELR2 LATS2 MAP2K3 MAP2K5 MUC20 MYC NF2 PABPC1 PCBD2 PIK3R1 PLCG1 PLXNB1 PTPN11 PTPRB PTPRJ RAF1 RANBP10 RANBP9 RASSF1 SHC1 SMC1A SNAPIN SNX2 SOCS1 SPSB1 SRC STAT3 STK11 TERT TP53 VAV1	56 interacting genes: ADAP1 ADAP2 APC AR ATM AXL BACE1 BRCA1 CACNA1G CALB1 CBS CCND1 CDK11B CLEC7A DDX4 DISC1 DYRK1B ENTPD1 ESR1 EXOC2 FMR1 HIPK2 HMBS HNF4G ITGAL ITGB2 L1CAM LMNA MAPK6 MET MKLN1 MPHOSPH8 NCOA6 NCOR2 PPARD PPARG PPP1CA PRKACA RAF1 RAN S100A7 SMAD2 SMAD3 SMAD9 SOS1 SPOP SPP1 TFRC THRA THRB TP53 TP73 UCHL1 USP11 WNK1 YPEL5
Entrez ID		4233	10048
HPRD ID		01280	04835
Ensembl ID		ENSG00000105976	ENSG00000010017
Uniprot IDs		A0A024R728 A0A024R759 B4DLF5 E6Y365 P08581	A0A024QZW3 Q96S59
PDB IDs		1FYR 1R0P 1R1W 1SHY 1SSL 1UX3 2G15 2RFN 2RFS 2UZX 2UZY 2WD1 2WGJ 2WKM 3A4P 3BUX 3C1X 3CCN 3CD8 3CE3 3CTH 3CTJ 3DKC 3DKF 3DKG 3EFJ 3EFK 3F66 3F82 3I5N 3L8V 3LQ8 3Q6U 3Q6W 3QTI 3R7O 3RHK 3U6H 3U6I 3VW8 3ZBX 3ZC5 3ZCL 3ZXZ 3ZZE 4AOI 4AP7 4DEG 4DEH 4DEI 4EEV 4GG5 4GG7 4IWD 4K3J 4KNB 4MXC 4O3T 4O3U 4R1V 4R1Y 4XMO 4XYF 5DG5 5EOB 5EYC 5EYD 5HLW 5HNI 5HO6 5HOA 5HOR 5HTI 5LSP 5T3Q 5UAB 5UAD 5UAF 5YA5 6GCU 6I04 6SD9 6SDC 6SDD 6SDE	5JI7 5JI9 5JIU
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?